Scarica l'app Stockscreener
6.83
0.44%
-0.03
Pre-mercato:
6.81
-0.02
-0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$6.86
Aprire:
$6.96
Volume 24 ore:
1.31M
Relative Volume:
0.42
Capitalizzazione di mercato:
$485.78M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-4.1646
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
+9.63%
1M Prestazione:
-17.21%
6M Prestazione:
+8.76%
1 anno Prestazione:
-26.16%
Intervallo 1D:
$6.7329
$7.005
Intervallo di 1 settimana:
$6.4089
$7.005
Portata 52W:
$5.275
$14.84
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
6.83 | 485.78M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth? - Simply Wall St
Altimmune's SWOT analysis: pemvidutide stock shows promise in obesity, NASH markets - Investing.com
Altimmune (NASDAQ:ALT) Shares Gap UpTime to Buy? - MarketBeat
Altimmune (NASDAQ:ALT) Now Covered by Stifel Nicolaus - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Geode Capital Management LLC Acquires 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Barclays PLC Raises Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Down 5.9%Here's Why - MarketBeat
Altimmune Could Find A Partner For Its Phase 3 Exercise (NASDAQ:ALT) - Seeking Alpha
(ALT) Technical Data - Stock Traders Daily
Jim Cramer on Altimmune, Inc. (ALT): ‘Healthcare Is So Out Of Fashion’ - Insider Monkey
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate - Yahoo Finance
Altimmune, Inc. (NASDAQ:ALT) Shares Sold by State Street Corp - MarketBeat
Altimmune (NASDAQ:ALT) Stock Price Down 4.6%Should You Sell? - MarketBeat
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds - MSN
Altimmune (ALT) Gains on Nasdaq Biotechnology Index Inclusion - GuruFocus.com
Why Altimmune Was Such a Robustly Healthy Stock on Thursday - MSN
Altimmune (NASDAQ:ALT) Trading Up 4.7%Here's Why - MarketBeat
Altimmune joins Nasdaq Biotechnology Index - Investing.com
Altimmune Joins Nasdaq Biotechnology Index, Gears Up for Pivotal MASH Drug Trial Data in 2025 - StockTitan
(ALT) Trading Report - Stock Traders Daily
Altimmune (NASDAQ:ALT) Stock Price Down 5.1%Should You Sell? - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity stock outlook - Investing.com
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Altimmune 2025: Redefining Obesity And MASH Treatment (NASDAQ:ALT) - Seeking Alpha
Virtu Financial LLC Makes New $674,000 Investment in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Up 4.9%Still a Buy? - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune reports positive trial results for liver disease drug By Investing.com - Investing.com Nigeria
Altimmune reports positive trial results for liver disease drug - Investing.com India
Trend Tracker for (ALT) - Stock Traders Daily
Altimmune Stock Up More Than 25% in a Month: Here's Why - MSN
Portolan Capital Management LLC Sells 579,266 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook By Investing.com - Investing.com South Africa
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook - Investing.com Canada
Looking At Altimmune's Recent Unusual Options Activity - Benzinga
Altimmune shares surge on CEO's CNBC appearance By Investing.com - Investing.com Canada
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On WednesdayAltimmune (NASDAQ:ALT), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
Altimmune CEO on what’s next for its experimental obesity drug - CNBC
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Altimmune Inc Azioni (ALT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Drutz David | Director |
Aug 19 '24 |
Option Exercise |
2.55 |
41,750 |
106,375 |
63,708 |
| Drutz David | Director |
Aug 19 '24 |
Sale |
6.90 |
16,011 |
110,547 |
41,958 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
44,990 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
39,016 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '24 |
Option Exercise |
0.00 |
7,775 |
0 |
55,965 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
6,166 |
0 |
49,991 |
| Garg Vipin K | President and CEO |
Feb 02 '24 |
Option Exercise |
0.00 |
18,950 |
0 |
300,404 |
| Garg Vipin K | President and CEO |
Feb 01 '24 |
Option Exercise |
0.00 |
16,545 |
0 |
288,767 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
29,699 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '24 |
Option Exercise |
0.00 |
9,275 |
0 |
43,277 |
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):